ClinicalTrials.gg
RecruitingNCT07696832PROMISEUpdated Oct 21, 2026

Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

An observational study in Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative and Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2, sponsored by Guangdong Association of Clinical Trials. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Guangdong Association of Clinical Trials · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
265
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials — 10 open to participants now, 13 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Guangdong Association of Clinical Trials.

Planned enrollment
6th of 10
265 · median 358
Started
2026
with 2 others
Observational
10 of 32
3 open now
Primary completion
2027-05
later than 6 of 12 live
Registered
30th of 32
by date

Among the 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials, this one is the 6th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2026, is one of 10 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 30th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

10 of the 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials, or all of them as a file.
02

Study summary

The treatment decisions, assessment schedule, and study procedures in this research will adhere to the routine clinical practice of each participating center. The specifics are as follows:

Treatment Decisions: Treatment will be administered in accordance with the officially approved drug label for Ivonescimab by the National Medical Products Administration (NMPA) and the latest domestic and international guidelines. Eligible patients meeting the inclusion criteria will receive first-line Ivonescimab monotherapy until disease progression or unacceptable toxicity occurs. The recommended dosage of Ivonescimab is 20 mg/kg administered intravenously every 3 weeks. Each infusion should be completed over 60 minutes (± 10 minutes). For patients who cannot tolerate the 60-minute (± 10 minutes) infusion, the duration may be extended to a maximum of 120 minutes (± 10 minutes). Dosing may be interrupted or permanently discontinued based on individual patient safety and tolerability; however, dose increases or reductions are not recommended. Dose modification and management of adverse events will follow the drug label and relevant guidelines. Any other concomitant supportive care or medications during the study period should be based on a comprehensive patient assessment, excluding contraindications explicitly stated in the label or guidelines, and administered according to the routine clinical practice of each center.

Assessment Plan: The timing, items, and frequency of all assessments, including tumor imaging evaluations and laboratory tests, will follow the routine clinical practice of each participating center.

Study Procedures: This study does not mandate protocol-defined study visits. A suggested visit schedule is provided solely to facilitate unified data collection and management.

Investigators will prospectively and continuously collect clinical data for all patients who provide signed informed consent and meet the eligibility criteria via an Electronic Data Capture (EDC) system until a study endpoint event occurs or the study concludes.

03

Conditions studied

  • Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC
  • EGFR Mutation-negative and ALK Rearrangement-negative
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2
  • No Prior Systemic Therapy Received for the Advanced or Metastatic Disease
  • PD-L1 Positive, as Determined by a Validated Assay

Keywords

  • NSCLC
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study population consists of adult patients with locally advanced or metastatic, driver gene-negative, PD-L1-positive non-small cell lung cancer (NSCLC) who initiate ivonescimab monotherapy as first-line systemic treatment in routine clinical practice. Eligible patients will be consecutively identified and enrolled from multiple participating centers in China. Clinical, pathological, and imaging data will be collected from medical records and follow-up visits to describe real-world effectiveness and safety outcomes associated with ivonescimab treatment in this setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in the study and provision of written approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
  2. Age ≥ 18 years at enrollment, male or female.
  3. or cytologically confirmed locally advanced (Stage IIIB/IIIC) or (Stage IV) non-small cell lung cancer (NSCLC) according to the International Association for the Study of Lung Cancer (IASLC) 9th edition TNM classification, and judged by the investigator as not amenable to curative surgery or definitive concurrent chemoradiotherapy.
  4. (ECOG) performance status (PS) of 0-2.
  5. ≥ 3 months.
  6. Tumor tissue expression positive, defined as tumor proportion score (TPS) ≥ 1% (any antibody clone), as determined by a central laboratory or a qualified pathology department accredited by the study site. If PD-L1 status has not been previously tested, the subject must provide tumor tissue samples (archived or freshly obtained) obtained at or after the diagnosis of locally advanced or metastatic disease, approximately 10-15 unstained slides, for PD-L1 testing.
  7. Subjects with actionable driver alterations including EGFR exon 21 insertions, c-MET aberrations (amplification/overexpression/exon 14 skipping mutation), BRAF V600E, , KRAS G12C, etc., for whom immunotherapy remains a primary/optional/standard treatment, and who are assessed by the investigator as likely to benefit from ivonescimab, are permitted to enroll. For subjects with non-squamous histology, testing for actionable driver mutations must be performed prior to enrollment. For subjects with squamous histology, testing is recommended; if not performed, enrollment may proceed based on clinical judgment (e.g., male smokers may be exempted from testing).
  8. No prior systemic anticancer therapy for locally advanced or metastatic NSCLC. Subjects who have received /adjuvant therapy with curative intent are eligible if the time from last treatment to recurrence/metastasis is > 6 months.
  9. At least one at baseline per (RECIST) version 1.1.
  10. The treating physician has decided to initiate first-line therapy with ivonescimab monotherapy for this subject.
  11. Adequate organ function and reserve to tolerate the study treatment, as judged by the investigator based on clinical practice.
  12. Urine dipstick protein ≤ 1+ is eligible; if ≥ 2+, a 24-hour urine protein quantification must be performed and the result must be ≤ 1 g/24h for enrollment.
  13. Non-sterilized male subjects and female subjects of must agree to use effective measures from the screening period until at least 120 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria

  1. Histological diagnosis containing small cell carcinoma or neuroendocrine carcinoma components.
  2. Currently participating in another interventional clinical study.
  3. Known actionable driver alterations in *EGFR*, *ALK*, *ROS1*, *RET*, or other driver genes for which approved therapies are available.
  4. History of severe bleeding tendency or coagulation disorders; bleeding symptoms within 1 month before the first dose, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing up or expelling ≥ 1 teaspoon of fresh blood or small blood clots, or expectorating only blood without sputum; subjects with blood-streaked sputum are eligible), or nasal bleeding (excluding epistaxis and blood-tinged postnasal drip).
  5. Radiologically confirmed tumor invasion of major blood vessels (e.g., aorta, central arteries/veins), vital organs (heart, trachea, esophagus, main bronchus), or encasement of major vessels with luminal stenosis. Presence of risk of esophagotracheal/pleural fistula; or pulmonary lesions with cavitation/necrosis assessed as having a life-threatening bleeding risk.
  6. Prior treatment with systemic immunotherapy targeting tumor immune evasion mechanisms, including (e.g., PD-1/PD-L1, CTLA-4, TIGIT, or LAG3 inhibitors) or immune checkpoint agonists (e.g., 0, CD137, ICOS, OX40, GITR antibodies), or cellular immunotherapy; or prior treatment with systemic anti-angiogenic therapy (including but not limited to bevacizumab and its biosimilars, ramucirumab, endostatin, apatinib, anlotinib, etc.).
  7. Active central nervous system (CNS) lesions that have not shown significant symptom improvement after targeted therapy (e.g., surgery, radiotherapy). Untreated asymptomatic (i.e., no neurological symptoms, no requirement for therapy, and no significant perilesional edema) are allowed.
  8. Presence of brainstem, , spinal cord metastases, or spinal cord compression.
  9. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis; or evidence of active pneumonitis on chest CT during screening; or acute exacerbation of within 1 month before the first dose. Subjects with a history of radiation pneumonitis (which has become fibrotic) are allowed.
  10. Occurrence of any of the following within 6 months before the first dose: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass grafting, congestive heart failure ( [NYHA] Class ≥ II), cerebrovascular accident (stroke), (TIA), or arterial/venous thromboembolic events of National Cancer Institute (NCI CTCAE) Grade ≥ 3 (e.g., pulmonary embolism, deep vein thrombosis, except asymptomatic catheter-related thrombosis); presence of severe arrhythmias requiring treatment (e.g., atrial fibrillation, supraventricular tachycardia, etc.), prolongation (male > 450 ms, female > 470 ms), or poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg); or history of hypertensive crisis or hypertensive encephalopathy.
  11. History of immunodeficiency; positive test for antibody; currently receiving long-term systemic corticosteroid therapy.
  12. Known active tuberculosis (TB); subjects suspected of active TB must undergo clinical examination to rule it out; known active syphilis infection.
  13. History of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  14. Severe infection within 4 weeks before the first dose, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia.
  15. Major surgery or severe trauma within 30 days before the first dose, or planned major surgery within 30 days after the first dose (as judged by the investigator); minor local surgery (excluding peripherally inserted central catheter [PICC] and venous port implantation) within 7 days before the first dose.
  16. Known history of severe (Grade ≥ 3) reaction to ivonescimab, any of its , or other monoclonal antibodies.
  17. Any severe psychiatric or social condition that, in the investigator's judgment, may interfere with study compliance or data reliability.
  18. Concomitant diseases or medications that, in the investigator's judgment, may affect treatment compliance or patient safety during the study period.
  19. Pregnant or breastfeeding women.
  20. Any other condition deemed by the investigator as inappropriate for enrollment.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
265 participants (estimated)
Patient registry
No

Groups and cohorts

  • First-line Ivonescimab Monotherapy in PD-L1-Positive NSCLC

    This cohort includes adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are negative for known oncogenic driver alterations (e.g., EGFR, ALK, ROS1, RET) and have PD-L1-positive tumors. All patients receive ivonescimab monotherapy as first-line systemic treatment in routine clinical practice. Patients will be enrolled consecutively from multiple centers in China and followed prospectively to assess real-world effectiveness and safety.

    Drug: Ivonescimab Injection

Interventions

  • DrugIvonescimabStudies of IvonescimabIvonescimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In accordance with the officially approved drug label for Ivonescimab by the National Medical Products Administration (NMPA) and the latest domestic and international guidelines, eligible patients enrolled in the study will receive first-line Ivonescimab monotherapy until disease progression or unacceptable toxicity occurs. The recommended dosage of Ivonescimab is 20 mg/kg administered via intravenous infusion every 3 weeks. Each infusion should be completed over 60 minutes (± 10 minutes). For patients intolerant to the 60-minute (± 10 minutes) infusion, the duration may be extended to a maximum of 120 minutes (± 10 minutes). Dosing may be interrupted or permanently discontinued based on individual patient safety and tolerability; however, dose increases or reductions are not recommended. Dose modification and adverse event management will follow the instructions in the drug label and relevant guidelines. Any concomitant supportive treatments or medications administered during the s

06

What researchers measure

Primary outcomes

  1. median rwPFS

    Real-world median progression-free survival (median rwPFS) assessed by the investigator per RECIST v1.1 is defined as the time from the first dose of Ivonescimab to the first documented disease progression (PD) as determined by the treating physician in the medical records, or death from any cause, whichever occurs first.

    Time frame: From date of first dose to date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 36 months.

Secondary outcomes

  1. Real-world Duration of Response (rwDoR)

    Real-world duration of response (rwDoR) is defined as the time from the date of first documented complete response (CR) or partial response (PR) to the date of first documented disease progression or death from any cause, whichever occurs first, as recorded in routine clinical practice. Tumor response will be assessed by the treating physician based on radiologic evaluations and clinical judgment, generally guided by RECIST v1.1 where available.

    Time frame: From date of first documented CR/PR to date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 36 months.

  2. Overall Survival (OS)

    Overall survival (OS) is defined as the time from the date of first Ivonescimab administration to death from any cause. Patients who are alive at the time of analysis or lost to follow-up will be censored at the date they were last known to be alive according to medical records or follow-up contacts.

    Time frame: From date of first dose to date of death from any cause, assessed up to 60 months.

  3. Real-world Time to Response (rwTTR)

    Real-world time to response (rwTTR) is defined as the time from the date of first Ivonescimab administration to the date of first documented CR or PR in routine clinical practice. Tumor response will be evaluated by the treating physician based on radiologic assessments and clinical judgment, generally guided by RECIST v1.1 where available.

    Time frame: From date of first dose to date of first documented CR/PR, assessed up to 36 months.

  4. Real-world Objective Response Rate (rwORR)

    Real-world objective response rate (rwORR) is defined as the proportion of patients who achieve a best overall response of CR or PR during Ivonescimab treatment in routine clinical practice. The denominator will include all patients in the effectiveness analysis set. Responses will be determined by the treating physician based on radiologic assessments and clinical judgment, generally guided by RECIST v1.1 where available.

    Time frame: Baseline and post-baseline tumor assessments during follow-up, assessed up to 36 months.

  5. Real-world Disease Control Rate (rwDCR)

    Real-world disease control rate (rwDCR) is defined as the proportion of patients whose best overall response is CR, PR, or stable disease (SD) during Ivonescimab treatment in routine clinical practice. The denominator will include all patients in the effectiveness analysis set. Tumor responses will be determined by the treating physician based on radiologic assessments and clinical judgment, generally guided by RECIST v1.1 where available.

    Time frame: Baseline and on-treatment tumor assessments during follow-up, assessed up to 36 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the primary and key secondary endpoints, as well as the study protocol and statistical analysis plan, may be shared with qualified researchers upon reasonable request after publication of the main study results. Data will be shared following approval of a methodologically sound proposal and completion of a data use agreement, in accordance with applicable laws and institutional policies.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: De-identified IPD and supporting documents will be available after publication of the primary results of this study or regulatory submission (whichever occurs first), and after review and approval of a data sharing request by the sponsor and/or principal investigators. Data are planned to be available for at least 5 years from the date of the primary publication, or longer if considered scientifically appropriate and feasible.

Access criteria: Access to de-identified IPD and supporting documents will be provided to qualified researchers affiliated with academic or public research institutions who submit a scientifically sound and ethically appropriate research proposal. Requests should include a detailed analysis plan and will be reviewed by the sponsor and/or a designated review committee. Upon approval, requestors will be required to sign a data use agreement that defines the scope of use, data protection measures, and publication requirements. Data will be shared through a secure data transfer method or controlled-access platform in accordance with applicable laws, institutional policies, and ethics committee requirements in China.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2027, 15 months after the start.

Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 15 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2026
First posted
Jul 10, 2026
StartActual
Jan 20, 2026
Primary completionEst.
May 15, 2027
CompletionEst.
Jun 30, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07696832
Lead sponsor
Guangdong Association of Clinical Trials
Responsible party
Jin-Ji Yang (Principal Investigator, Guangdong Association of Clinical Trials) — Principal investigator
First posted
Jul 10, 2026
Start date
Jan 20, 2026
Primary completion
May 15, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Hao Sun, Phd
Contact
sunhao@gdph.org.cn
+86 16620178852

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion